The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2011, Pages 349-357

  Kopylov, U ^a   Mantzaris, G J ^b   Katsanos, K H ^c   Reenaers, C ^d   Ellul, P ^e   Rahier, J F ^f   Israeli, E ^g   Lakatos, P L ^h   Fiorino, G ⁱ   Cesarini, M ^j   Tsianos, E V ^c   Louis, E ^d   Ben Horin, S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e MATER DEI HOSPITAL   (Malta)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CROHN DISEASE; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650855456     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04523.x     Document Type: Article

References (17)

1. Hanauer S, Feagan B, Kichtenshtein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
2. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
3. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
4. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
5. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
6. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
7. Requeiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9.
8. Van Assche G, Vermeire S, Rutgeerts P,. Management of loss of response to anti-TNF drugs: change the dose or change the drug? J Crohn's Colitis 2008; 2: 348-51.
9. Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis 2008; 14: 432-4.
10. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
11. Klotz U, Teml A, Schwab M,. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-60.
12. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in Rheumatoid Arthritis. Arthritis Rheum 2002; 46: 1451-9.
13. Kaplan GG, Hur C, Korzenik J, Sands BE,. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20.
14. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab lies within the Fab fragment, but measurement of antibodies against the intact infliximab molecule shows superior clinical usefulness. Gut 2010 [Epub ahead of print].
15. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
16. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
17. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.